SCHEMBL2471306

SCHEMBL2471306

C[Si](C)(C)CCOCn1nc(C#N)c2cc(N)ccc21

nearest known ligand 0.35

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.35
CNR1 P21554 2/20 0.33
CNR2 P34972 2/20 0.33
ACHE P22303 1/20 0.33
KDM4E B2RXH2 1/20 0.31
USP2 O75604 1/20 0.31
ALDH1A1 P00352 1/20 0.31
DGAT1 O75907 2/20 0.31
PFKFB2 O60825 1/20 0.30
PFKFB1 P16118 1/20 0.30
PFKFB3 Q16875 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27227858 0.91 NPC1 (0.33) NPC1DGAT1
SCHEMBL30861073 0.91 NPC1 (0.33) NPC1DGAT1
SCHEMBL28906224 0.86 DGAT1 (0.41) NPC1DGAT1PFKFB2PFKFB1PFKFB3
SCHEMBL30138980 0.86 DGAT1 (0.41) NPC1DGAT1PFKFB2PFKFB1PFKFB3
SCHEMBL3517125 0.83 CNR1 (0.37) NPC1CNR1CNR2ACHEKDM4E
SCHEMBL31512383 0.83 ELANE (0.40) NPC1KDM4EDGAT1
SCHEMBL17849502 0.83 ELANE (0.40) NPC1KDM4EDGAT1
SCHEMBL4006988 0.82 NPC1 (0.34) NPC1CNR1CNR2ACHE
SCHEMBL29172538 0.81 NPC1 (0.37) NPC1CNR1CNR2ACHEKDM4E
SCHEMBL14442048 0.81 ELANE (0.47) CNR1CNR2ACHEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546404-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME (US) 2013-10-01 US disclosed
US-8546404-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME (US) 2013-10-01 US disclosed
CN-101370784-B Compound serving as ERK inhibitors SCHERING CORPORTAION 2012-10-10 CN disclosed
EP-1966151-B1 POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS SCHERING CORP (US) 2011-10-05 EP disclosed
US-20090118284-A1 Novel compounds that are ERK inhibitors MERCK SHARP & DOHME LLC 2009-05-07 US disclosed
US-20090118284-A1 Novel compounds that are ERK inhibitors MERCK SHARP & DOHME LLC 2009-05-07 US disclosed
CN-101370784-A Polycyclic indazole derivatives that are erk inhibitors SCHERING CORP (US) 2009-02-18 CN disclosed
US-20070191604-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-08-16 US disclosed
US-20070191604-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118284-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPK10 NPC1 2087/4885CNR1 2879/4885CNR2 3806/4885
US-20070191604-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPKAPK2 NPC1 2655/4885CNR1 2910/4885CNR2 3856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.